73 related articles for article (PubMed ID: 17538190)
1. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
Fujiwara Y; Sekine I; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Simmyo Y; Fukui T; Yamada K; Tamura T
Jpn J Clin Oncol; 2007 May; 37(5):358-64. PubMed ID: 17538190
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
Makihara K; Azuma S; Kawato N; Ueno H; Nakata I
Cancer Chemother Pharmacol; 2015 Feb; 75(2):273-9. PubMed ID: 25432775
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Read W; McLeod H; Govindan R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D; Guchelaar HJ; Gelderblom H
Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M
Am J Clin Oncol; 2006 Oct; 29(5):503-7. PubMed ID: 17023787
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
[TBL] [Abstract][Full Text] [Related]
17. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Zhang XR; Zhu YZ; Xiu QY; Han FC; Liu DQ; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):777-9. PubMed ID: 17366795
[TBL] [Abstract][Full Text] [Related]
20. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
